Related Experiment Videos
[S-1 treatment against advanced HCC]
Masato Nakamura1, Hiroaki Nagano, Shigeru Marubashi
1Dept. of Surgery, Osaka University, Graduate School of Medicine, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 11, 2006
Summary
A new S-1 and interferon-alpha combination therapy shows significant anti-tumor effects against advanced hepatocellular carcinoma (HCC) with distant metastases. This treatment offers a promising option with no severe adverse effects for patients with advanced HCC.
Area of Science:
- Hepatobiliary cancers
- Medical oncology
- Translational cancer research
Context:
- Advanced hepatocellular carcinoma (HCC) with portal vein thrombus presents significant treatment challenges.
- Intra-arterial 5-fluorouracil (5-FU) infusion combined with interferon-alpha demonstrated efficacy in controlling primary hepatic lesions.
- The emergence of distant metastases necessitates novel therapeutic strategies for advanced HCC.
Purpose:
- To evaluate the efficacy of S-1 and interferon-alpha combination chemotherapy in patients with advanced HCC exhibiting distant metastases.
- To assess the safety and tolerability of this combination regimen.
Summary:
- A combination chemotherapy of S-1 and interferon-alpha was administered to advanced HCC patients with distant metastases, following prior treatment with interferon-alpha and arterial 5-FU infusion.
- Complete response (CR) in anti-tumor effect against distant metastases was observed.
- The treatment exhibited no severe adverse effects, indicating a favorable safety profile.
Impact:
- The S-1 and interferon-alpha combination therapy represents a potentially effective treatment modality for advanced HCC with distant metastases.
- This approach may improve outcomes for a patient population with limited therapeutic options.
- Further investigation into this combination therapy is warranted for advanced HCC management.